DNA genotyping is a powerful technology that allows the identification of genetic variations that can lead to an increased risk of developing certain diseases. Additionally, genotyping has a fundamental role in companion diagnostics, as it enables the characterization of patients’ genetic profiles that can be used to guide treatment decisions.
Here, we will introduce two novel master mixes developed to provide PCR-based identification of mutations directly from the clinical samples, such as blood, plasma or FFPE tissue, bypassing DNA extraction and streamlining the analysis of both liquid and tissue biopsies.

Speakers:
Mihai-Nicolae Podaru, PhD (R&D Senior Scientist, Meridian Bioscience)

Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)